Discover and read the best of Twitter Threads about #ISPOREurope
Most recents (6)
I'm now live tweeting from the #ISPOREurope session Much Ado About Little: Dealing with Limited RCT Evidence for Early HTA and Reimbursement Decisions with @MJSculpher, @SBujkiewicz, Eva Dietrich, Steven Palmer from @CHEyork, and @UweSiebert9 
@MJSculpher starts by setting the context and introducing the speakers.
@UweSiebert9 is the 1st plenary speaker, on causal inference in #RCTs and #RWE
#ISPOREurope
@UweSiebert9 is the 1st plenary speaker, on causal inference in #RCTs and #RWE
#ISPOREurope
When do we need causal inference methoss? when there's no randomisation; or the randomisation was broken (e.g. treatment switches)
Throughout his talk, Uwe will use the example of 2nd line treatment in women with ovarian cancer who progressed
#ISPOREurope
Throughout his talk, Uwe will use the example of 2nd line treatment in women with ovarian cancer who progressed
#ISPOREurope
Next, live from #ISPOREurope IP8: Integrating Patient Preference into Health Technology Assessment- Can Patient Preferences be Incorporated into the ICER? w/Esther de Bekker-Grob @erasmusuni, Kevin Marsh @evideraglobal Mendwas Dzingina @pfizer & @JacolineBouvy at
@NICEComms
@NICEComms
Esther de Bekker-Grob starts with the questions addressed in this panel
The background is that, given the increased focus on pt preferences, #HTA should not fall behind
#ISPOREurope
The background is that, given the increased focus on pt preferences, #HTA should not fall behind
#ISPOREurope
Why should #HTA consider pt preferences?
To improve adherence, to increase pt satisfaction, to make HTA decision making more informed & transparent, and it is ethical to listen to the pt voice.
#ISPOREurope
To improve adherence, to increase pt satisfaction, to make HTA decision making more informed & transparent, and it is ethical to listen to the pt voice.
#ISPOREurope
Fellow #ISPORians I'll be logging in to the #WomenInHEOR #ISPOREurope session Adapting to the ‘New Normal’ 😀
W/ @juliaslejko, Olivia Wu, @DrBlytheAdamson, @nancydevlin1, Ebere Onukwugha and @LouiseTimlin - a panel of #HEOR stars 🤩
W/ @juliaslejko, Olivia Wu, @DrBlytheAdamson, @nancydevlin1, Ebere Onukwugha and @LouiseTimlin - a panel of #HEOR stars 🤩
To start, @juliaslejko presents the context for the @ISPORorg #WomenInHEOR initiative.
There is evidence that diversity pays off in terms of companies' profitability. But women are under-represented, and there is a leaky pipeline in academia
#ISPOREurope
There is evidence that diversity pays off in terms of companies' profitability. But women are under-represented, and there is a leaky pipeline in academia
#ISPOREurope
@ISPORorg board members and staff are quite diverse. What about ISPOR conferences, like #ISPOREurope?
Gender diversity has improved in ISPOR conferences 👏
But there is still some way to go - that's ISPOR intention and aspiration
Gender diversity has improved in ISPOR conferences 👏
But there is still some way to go - that's ISPOR intention and aspiration
Which @ISPORorg #ISPOREurope session would you like a live twitter thread tomorrow? You can help me choose by voting 🗳️😀
One option is IP6: How Should Pharmaceutical Companies and Patients Served By Health Systems Share the Value Generated By New Medicines? with Danny Palnoch from @NHSEngland, @bs_woods from @CHEyork, Jens Grueger from @UW_Pharmacy and Patricia Danzon from @Wharton #ISPOREurope
Or IP8: Integrating Patient Preference into Health Technology Assessment- Can Patient Preferences be Incorporated into the ICER? w/ Esther de Bekker-Grob @erasmusuni, Kevin Marsh @evideraglobal, Mendwas Dzingina @pfizer & @JacolineBouvy at @NICEComms
#ISPOREurope
#ISPOREurope
I'm now logging into #ISPOREurope live session IP3: The Meaning of Cure – the Search for What? with @NRLatimer, @BettinaRyll, and K. Jack Ishak and Ágnes Benedict from @evideraglobal ispor-europe2020.secure-platform.com/a/gallery/roun…
Jack Ishak starts by introducing panellists and setting the motivation for this panel: therapies that have raised the potential of cure, given the plateau since in the OS and PFS curves
#ISPOREurope
#ISPOREurope
This raises analytical challenges on how to project the OS and PFS curves over the long term. Mixture cure models have been used. Here, the curve is a weighted average of the survival of cured and uncured, where the weight is prop cured.
#ISPOREurope
#ISPOREurope
Missed the panel “Value-Based Pricing and Market Allocative Efficiency: How Should Cost-Effectiveness Thresholds be Set to "Optimally" Distribute Value between Payers and Developers?” w @mikepaulden, @MBerdud & Laura Vallejo-Torres at #ISPOREurope?
ispor-europe2020.secure-platform.com/a/gallery/roun…
ispor-europe2020.secure-platform.com/a/gallery/roun…
Laura starts with what her presentation will cover:
1-What is a #CostEffectiveness #Threshold for?
2-What should it reflect?
3-How to estimate it empirically?
4-What are the consequences of setting the decision threshold at != from empirical threshold?
#ISPOREurope
1-What is a #CostEffectiveness #Threshold for?
2-What should it reflect?
3-How to estimate it empirically?
4-What are the consequences of setting the decision threshold at != from empirical threshold?
#ISPOREurope
What is a #Threshold? It is to find out if an intervention generates more benefits gained than lost via the opportunity cost, AND/OR to identify a decision threshold that incorporates other policy objectives.
#ISPOREurope
#ISPOREurope
